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Abstract
Background: Although Chlamydia trachomatis is the most commonly reported pathogen that causes urogenital
infection such as urethritis or cervicitis, Ureaplasma parvum and Ureaplasma urealyticum, which are commensals in
the genital tract, have also now been recognized as contributors to urogenital infection. However, whether the
presence of either U. parvum or U. urealyticum is related to that of C. trachomatis in the urogenital tract remains
unknown. We therefore attempted to estimate by PCR the prevalence of C. trachomatis, U. parvum and U. urealyticum
in endocervical samples obtained from healthy women attending their first prenatal visit in Sapporo, Japan.
Methods: The samples were taken from 303 apparently healthy women, and the extracted DNAs (n = 280) were
used for PCR detection targeting C. trachomatis, U. parvum and U. urealyticum. Statistical analysis of the data was
performed by Fisher’s exact test.
Results: PCR detection revealed that the prevalence of C. trachomatis, U. parvum and U. urealyticum was 14.3%
(40/280), 41.7% (117/280) and 8.9% (25/280), respectively. C. trachomatis ompA genotype D was most frequently
identified. Surprisingly, either C. trachomatis or Ureaplasma spp. was detected in almost half of the healthy women.
Mixed infection of C. trachomatis with either U. parvum or U. urealyticum was also observed in 9.2% (26/280) of the
women. There was a significant association between C. trachomatis and either U. parvum (p = 0.023) or Ureaplasma
total (p = 0.013), but not U. urealyticum (p = 0.275).
Conclusion: This study demonstrated that the presence of Ureaplasma had a significant effect on the presence of
C. trachomatis in the genital tract of healthy women, suggesting that mixed infection is an important factor in
bacterial pathogenesis in the genital tract.
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Background
Urogenital tract infections are a major cause of morbidity
in sexually active individuals worldwide, therefore, the
World Health Organization has stated that sexually
transmitted diseases (STDs) rank second in importance
after cancer as treatable diseases in women. In particular,
Chlamydia trachomatis is the leading cause of bacterial
STD, with an estimated 5 million new cases annually
worldwide [1-3]. C. trachomatis infection can cause testi-
cular atrophy, epididymitis and orchitis in men, and duc-
tal obstruction, pelvic inflammatory disease, tubal
occlusion and extrauterine pregnancy in women [4-9].
However, the aetiology of most cases of chlamydial infec-
tion is undetermined and it could be multifactorial in
nature, because of complications with commensal bac-
teria or mixed infections with other pathogens [10-12].
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Ureaplasma are currently separated into two species:
Ureaplasma urealyticum and Ureaplasma parvum, which
are both thought to be genital tract commensals [13-17].
They are commonly found in healthy persons, therefore,
their pathogenic role can be difficult to prove in a small
population of individuals. Meanwhile, several studies have
reported that Ureaplasma are associated with some dis-
eases including non-gonococcal urethritis, pregnancy
complications and prenatal infections, more often than are
normal flora [18-20]. Thus, it might be that Ureaplasma
perturb homeostasis in the genital tract, which provides a
survival advantage for C. trachomatis. However, data
regarding mixed infection of C. trachomatis with Urea-
plasma are limited [13-15].
In the present study, we therefore attempted to esti-
mate by PCR and culture (C. trachomatis,i n c l u s i o n
forming assay; Ureaplasma, urease test), the prevalence
of C. trachomatis, U. parvum and U. urealyticum in
healthy women attending their first prenatal visit at a
community hospital in Sapporo, Japan.
Methods
Bacteria
C. trachomatis D/UW3 Cx strain (VR-855) and U. parvum
(ATCC-27813) were purchased from ATCC (Manassas,
VA, USA). C. trachomatis and U. parvum were propa-
gated in the HEp-2 cell culture system [21] and PPLO
medium [1.5% (w/v) PPLO powder, 20% (v/v) horse
serum, 5% (w/v) yeast extract, 1% (w/v) urea, 0.1% (w/v)
phenol red, antibiotics (10 μg/ml vancomycin; 1 μg/ml
amphotericin B), pH 6.0], respectively. The numbers of
infectious progenies for C. trachomatis were determined
as inclusion forming units (IFU) by counting chlamydial
inclusions formed in HEp-2 cells using fluorescein isothio-
cyanate (FITC)-conjugated monoclonal anti-Chlamydia
antibody specific to Chlamydia lipopolysaccharide (LPS)
(Denka Seiken Co. Ltd., Tokyo, Japan) [21]. The numbers
U. parvum were also determined as colony-forming units
(CFU) by counting colonies formed on the PPLO agar
under a phase-contrast microscope.
Endocervical samples
Three hundred and three samples were obtained from
apparently healthy women attending their first prenatal
visit at Toho Obstetrics and Gynecology Hospital [number
of deliveries, 1,332 per year (2010); number of caesarean
sections, 310 per year (2010); number of vacuum extrac-
tions, 106 per year (2010)], located on the outskirts of Sap-
poro City, Japan, from July 2010 to September 2010. The
average age (± SD) of healthy women attending this hospi-
tal was 28.28 ± 5.25 years, and the age distribution was as
follows: 94 (20-24 years), 93 (25-29 years), 59 (30-34
years), 25 (35-40 years), and nine (> 40 years). The sam-
ples were collected by scraping the endocervix of each
woman with a sterile cotton applicator. The applicator
was immediately immersed and resuspended in 1 ml
sucrose-phosphate-glutamic acid buffer [SPG: 0.2 M
sucrose, 3.8 mM KH2PO4,6 . 7m MN a 2HPO4,5m M
L-glutamic acid (pH 7.4)][21], and stored at -80°C until
use.
Ethics
Written informed consent was obtained from all women,
and the study was approved by the ethics committees of
the Faculty of Health Sciences, Hokkaido University and
Toho Obstetrics and Gynecology Hospital.
DNA extraction
One hundred microlitres of SPG solution in each sample
was used for DNA extraction using a QIAmp DNA mini
kit (Qiagen, Valencia, CA, USA), according to manufac-
turer’s instructions. The solution was centrifuged at
18,900 × g for 30 min. Pellets were then used for DNA
extraction. The DNA was eluted in 50 μlo ft h ee l u t i o n
buffer supplied with the kit, quantitated spectrophotome-
trically and stored at -20°C until use.
PCR detection and lineage analysis with ompA full
sequences
Table 1 shows primer sets and conditions for PCR amplifi-
cation of C. trachomatis [22], U. parvum [13], U. urealyti-
cum [13], and most bacteria [23]. The quality of extracted
DNA was confirmed by PCR amplification using universal
primers that target bacterial 16S rRNA, which is conserved
across a broad spectrum of bacteria. DNA samples that
resulted in negative PCR for bacterial 16S rRNA were dis-
carded. Finally, the samples (n = 280) that yielded PCR
products of the expected size were used for PCR amplifi-
cation of C. trachomatis (target gene, ompA) [22], U. par-
vum [target gene, 5’ ends of the multiple-banded antigen
gene (MBA) with upstream region] [13] and U. urealyti-
cum (target gene, MBA with upstream region) [13]. Tem-
plate DNA (2 μl) (average amount of DNA per sample:
63.64 ± 89.16 ng/μl) was used for each PCR. Reactions
were carried out in 25 μl reaction buffer [each dNTP, 200
μmol; 1× commercial reaction buffer (New England Bio-
labs, Herts, UK)] containing Taq DNA polymerase [0.625
U Taq DNA polymerase (New England Biolabs). The PCR
cycle consisted of 10 min denaturation at 94°C followed
by 30-45 cycles, each of 30 s denaturation at 94°C; 30 s of
annealing at 52-58°C; and 45 s of extension at 72°C. The
amplified products were separated by 1.2% agarose gel
electrophoresis and visualized by ethidium bromide stain-
ing. Each PCR was performed at least two times, for con-
firmation of PCR specificity and reproducibility. In
addition, to prevent contamination, the preparation of the
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ducts of ompA amplified in C. trachomatis-positive speci-
mens were fully sequenced (Macrogen, Seoul, Korea) and
each of the genotypes was determined through BLAST
search. Lineage analysis with ompA sequences was also
performed by the following method: C. trachomatis ompA
sequences were aligned with MUSCLE software [23].
Then, the phylogenetic tree was constructed using the
neighbour-joining method with MEGA5 software [24]. The
following reference sequences were used: A/Sa1 (M58938),
B/TW-5 (M17342), C/TW3 (M17343), D/B-120 (X62918),
E/Bour (X52557), F/IC-Cal3 (X52080), G/UW57
(AF063199), H/Wash (X16007), I/UW-12 (AF063200), J/
UW36 (AF063202), K/UW31 (AF063204), L1/440
(M36533), L2/434 (M14738), and L3/404 (X55700). Chla-
mydia muridarum MoPn (M64171) was also used as an
out-group sequence. The gene accession numbers of
sequences identified in this study were deposited in “DNA
Data Bank of Japan” and available from authors upon
request.
PCR detection limit for C. trachomatis and ureaplasmas
To determine the detection limit of PCR for C. trachomatis
and Ureaplasma spp., spike experiments were performed.
U. parvum was used as a representative Ureaplasma.S e v -
eral sets of 100 μl of SPG solution in the pooled swab sam-
ples, which proved negative for C. trachomatis and
Ureaplasma, were prepared. The sets were spiked with
serial dilutions of either C. trachomatis VR-855 from 10
-2
to 10
4 IFU or U. parvum ATCC-27813 from 10
-1 to 10
5
CFU per sample. The DNA extraction of spiked samples,
as well as from clinical specimen, was used for the PCR-
detection method with primer sets targeting to C. tracho-
matis ompA and Ureaplasma MBA as described above.
Biological detections
The presence of infectious C. trachomatis in the samples
confirmed as C. trachomatis-PCR positive was determined
by inclusion formation assay on HEp-2 cells. The presence
of viable Ureaplasma in the samples confirmed as either
U. parvum or U. urealyticum PCR-positive was also deter-
mined using a urease assay as follows. In brief, a sample
solution of 5 μl was diluted to 100 μl with SPG, and then
passed through a filter with a 0.22-μmp o r es i z e .T h ef i l -
trate was cultured in a total of 200 μl of PPLO medium at
37°C for 7 days. Samples that turned from yellow to red
after the incubation were considered Ureaplasma positive.
Statistical analysis
Comparison between the frequency of C. trachomatis and
that of U. parvum or U. urealyticum was done by Fisher’s
exact test (two-way ANOVA; Statview, Abacus Concepts
Inc., Piscatway, NJ, USA). A p value < 0.05 was considered
significant.
Results and discussion
Quality control of DNA extracted from endocervical
samples
We assessed by PCR amplification the bacterial flora in
the genital tract, to confirm whether extracted DNA was
Table 1 Primer sequences and PCR conditions used for this study
Microorganism Target gene Primer Sequence Annealing
condition;
Expected Reference [Reference
number]
Temperature/
cycle
fragment
size
Most bacteria 16S rRNA Forward
(Bac3)
5’-AGA GTT TGA TYM TGG CTC
AG-3’*
52/35 nearly full-
length
Horn et al., 1999 [22]
Reverse
(Bac4)
5’-CAK AAA GGA GGT CC-3’**
Chlamydia
trachomatis
ompA Forward
(CtOmp1)
5’-ATG AAA AAA CTC TTG AAA
TCG G-3’
55/35 1,100 bp Jurstrand et al., 2010
[23]
Reverse
(CtOmp2)
5’-ACT GTA ACT GCG TAT TTG
TCT G-3’
Ureaplasma
parvum
MBA gene with Forward
(UMS-57)
5’-(T/C)AA ATC TTA GTG TTC ATA
TTT TTT AC-3’
58/35 326/327 bp Kong et al., 2000 [13]
it upstream region*** Reverse
(UMA222)
5’-GTA AGT GCA GCA TTA AAT
TCA ATG-3’
Ureaplasma
urealyticum
MBA gene with it
upstream region
Forward
(UMS-170)
5’-GTA TTT GCA ATC TTT ATA
TGT TTT CG-3’
58/45 476 bp Kong et al., 2000 [13]
Reverse
(UMA263)
5’-TTT GTT GTT GCG TTT TCT-3’
*Y, C or T; M, A or C
**K, G or T
***MBA, 5’ ends of the multiple-banded antigen gene
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or Ureaplasma spp. Three hundred and three samples
were individually assessed by PCR with a primer set tar-
geting bacterial 16S rRNA. The average amount of DNA
was 63.64 ± 89.16 ng/μl, which indicated successful
DNA extraction, therefore, it was expected that all sam-
ples would be available for PCR. However, in 23 samples
(9.2%) PCR failed to amplify 16S rRNA gene, even
though the amount of extracted DNA was never low.
Therefore, the 23 samples without amplification were
omitted and the remaining 280 were used for this study.
Standard PCR techniques, which can be applied to ana-
lyse the entire microorganism community of complex
biological samples obtained from living individuals, has
been universally used. However, it is well known that
haemoglobin, lactoferrin, heparin, and bile acids, which
are ubiquitous to environments such as the genital tract,
inhibit PCR amplification [25]. This suggests that it is
absolutely necessary to check the DNA quality carefully
to confirm successful PCR amplification from genital
swab samples.
PCR detection of C. trachomatis, U. parvum and U.
urealyticum
The detection limit of the PCR for either C. trachomatis
ompA or Ureaplasma MBA with upstream region was
examined by using DNAs extracted from the pooled
genital swabs [confirmed that all targeted bacteria (C.
trachomatis and Ureaplasma spp.) were negative] that
had been spiked with defined numbers of either C. tra-
chomatis or U. parvum. The detection limit of the PCR
in spiked genital swabs for C. trachomatis and U. par-
vum (as a representative Ureaplasma)w a s1I F Ua n d
100 CFU per 100 μl of swab sample, respectively. The
spiked samples revealed that the PCR system allowed
stable and sensitive detection of each target DNA.
Although the PCR primers that targeted C. trachomatis
ompA for C. trachomatis detection were used for this
study, it has also been shown worldwide that cryptic
plasmid gene permits detection of C. trachomatis from
clinical specimens [26-28]. However, so far it has also
been reported that there is absence, variation or deletion
of the plasmid in C. trachomatis [29-31], in particular,
causing a clinical problem with false-negative results for
C. trachomatis in Europe [29-31]. Although plasmid
copy number is generally much higher than that of a
genomic gene, which increases the sensitivity of PCR
detection, we did not use cryptic plasmid for PCR tar-
geting of C. trachomatis detection to prevent false-nega-
tive results. Detection of U. parvum and U. urealyticum
with PCR primers targeting MBA genes with variable
regions has been well documented for Ureaplasma
detection [13,32-36] therefore, we selected this gene for
PCR detection of Ureaplasma spp. In fact, as shown in
Figure 1 (representative PCR results), each of the PCR
products was clearly visible, permitting us to make accu-
rate judgements.
Prevalence of C. trachomatis, U. parvum and U.
urealyticum
As shown in Figure 2, PCR detection revealed that the pre-
valence of C. trachomatis, U. parvum and U. urealyticum
was 14.3%, 41.7% and 8.9%, respectively. The prevalence of
C. trachomatis in healthy women has been estimated
worldwide. The detection frequency among healthy
women varies between countries and cities (46% Colombia
[37]; 22.9% England [38]; 3.9% USA (Baltimore) [39]; 0.2%
Australia [40]), probably depending on prevailing environ-
mental factors and population living habits. However, its
infectious frequency is believed to be around 10% on an
average from a global perspective [1,2]. As compared to
other studies with healthy women in Japan (~5.8% on aver-
age; 3.0-3.8% Tokyo [39,41]; 5.6% Fukuoka [42]; 8.3-8.8%
Miyasaki [43,44]; 1.7% Nasushiobara [45]; 9.5% Wako
[46]), the prevalence of C. trachomatis in Sapporo City that
we estimated (14.3%) was unique. Our result is supported
by a previous study showing a C. trachomatis detection fre-
quency of 11.3% in Sapporo [47]. Thus, the prevalence of
C. trachomatis in Sapporo, Japan, is likely to be high.
Although we cannot explain the exact reason for this high
prevalence, it may be related to the fact that the city has a
relatively large population (~2 million) with an active
nightlife, (Susukino district, ~3.7 km from the hospital),
which particularly attracts sexually active young people.
Figure 1 Representative PCR detection images showing C.
trachomatis, U. parvum and U. urealyticum amplification.N ,
negative control (molecular grade water); P, positive control (DNA
extracted from each of the bacteria).
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age group (20-24 years), who were more sexually active,
predictably increased from 14.3% to 23.4%.
PCR detection also revealed that the prevalence of
U. parvum and U. urealyticum was 41.7% and 8.9%,
respectively. Other studies with healthy women also have
reported that the detection frequency of U. parvum and
U. urealyticum was estimated at ~50% (57 and 87% Aus-
tralia [13,48]; 52% Japan [49]; 33.2 and 86.8% China [50];
86% Italy [51]; 17.9% Poland [52]) and 10% (6.1-19%
Australia [13]; 8.7% Japan [49]; 4.6-10.5% China [50]; 14%
Italy [51]; 2.6% Poland [52]). The findings with our data
suggested that the distribution of Ureaplasma is spreading
worldwide and that the species are commonly found in
healthy people as presumably commensal bacteria, there-
fore, their pathogenic role would be minimal [53-56].
Nevertheless, it has been increasingly reported that Urea-
plasma spp. are associated with non-gonococcal urethritis,
chorioamnionitis, preterm birth, perinatal morbidity, and
mortality, more often than are normal flora [53-55]. Thus,
our knowledge regarding the pathogenesis of Ureaplasma
still remains paradoxical and is limited, suggesting that
further, larger epidemiological studies with healthy people
and patients with urogenital disorders are needed.
The gold standard for bacterial detection from clinical
specimens is probably culture; therefore, we also assessed
whether C. trachomatis and Ureaplasma spp. in PCR-posi-
tive samples could be detected by using biological detection
systems, IFU assay and urease assay, respectively. However,
contrary to our expectation, the detection frequencies of
C. trachomatis and Ureaplasma spp. in PCR-positive sam-
ples decreased to 30% and 2%, respectively. Although it is
necessary to clarify the exact reason, it is possible that
freeze-thawing of samples crucially caused a decrease in
detection frequencies.
Mixed infection of C. trachomatis and Ureaplasma
Surprisingly, either C. trachomatis or Ureaplasma spp.
was detected in almost half of the healthy women (52.5%,
147/280), and mixed infection with C. trachomatis and
either U. parvum or U. urealyticum was observed in 9.2%
(26/280) (Figure 2, See overlapping area). It is intriguing
that there was a significant association between C. tracho-
matis and either U. parvum (p =0 . 0 2 3 )o rUreaplasma
total (p = 0.013), but not U. urealyticum (p = 0.275)
(Table 2). Meanwhile, several studies also estimated the
mixed infection frequency; however, correlation between
the frequency of C. trachomatis and either U. parvum or
U. urealyticum was limited, and has been considered less
serious in urogenital infections [56-58]. At present, we do
not have any explanation to resolve this contradiction. It is
possibly due to the particular experimental design, includ-
ing detection methods such as PCR or serology, or a lack
of accurate quality control for DNA extraction. Our study
revealed that U. parvum had a significant effect on the
presence of C. trachomatis in the genital tract of healthy
women, suggesting that mixed infection is an important
factor in bacterial pathogenesis of the genital tract. Mean-
while, whether this observation is limited to Sapporo City
remains unknown. In addition, there was no difference of
C. trachomatis frequency between U. parvum [20% (23/
117)] and U. urealyticum [20% (5/25)] positive samples.
This implies that U. urealyticum also may have a potential
effect on the presence of C. trachomatis as well as
U. parvum.
A ss h o w ni nF i g u r e3 ,w ea l s oe s t i m a t e dt h ef r e q u e n c y
of ompA genotypes among C. trachomatis that we
detected by direct full sequencing (n = 40). As a result, we
finally determined the following C. trachomatis ompA gen-
otypes: D (30%), B (2.5%), E (7.5%), F (12.5%), G (0.5%), I
(12.5%), J (5%), K (10%), and undetermined (17.5%).
Although C. trachomatis ompA genotype D was the most
frequently identified, there was no association of the geno-
type with either U. parvum or U. urealyticum.
Why does C. trachomatis co-infect with U. parvum in
the genital tract? So far, we do not have any definite expla-
nation. However, it is possible that the presence of U. par-
vum could provide some advantages for survival of
C. trachomatis in the genital tract, possibly through
directly or indirectly supplying tryptophan to overcome
the depletion of this amino acid inside the cells by inter-
feron g exposure [59,60].
Conclusion
Endocervical samples were taken from 303 women
attending their first prenatal visit at a community
Figure 2 Detection frequencies of C. trachomatis, U. parvum
and U. urealyticum in DNA extracted from genital swabs.
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280), amenable to 16S rRNA PCR amplification, were
analysed by PCR that targeted C. trachomatis, U. par-
vum and U. urealyticum. The prevalence of C. tracho-
matis, U. parvum and U. urealyticum was 14.3%, 41.7%
and 8.9%, respectively. Mixed infection with C. tracho-
matis with either U. parvum or U. urealyticum was
observed in 9.2% of the study population. Interestingly,
there was a statistical correlation between the frequency
of C. trachomatis and either U. parvum (p = 0.023) or
Ureaplasma total (p = 0.013), but not U. urealyticum
(p = 0.275). Thus, this study demonstrated that the pre-
sence of Ureaplasma had a significant effect on the pre-
sence of C. trachomatis in the genital tract of healthy
women.
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